Dysfunction of ubiquitin protein ligase MYCBP2 leads to cell resilience in human breast cancers.

ABSTRACT: Breast cancer is the most common type of cancer among women worldwide, and it is estimated that 294 000 new diagnoses and 37 000 deaths will occur each year in the United States alone by 2030. Large-scale genomic studies have identified a number of genetic loci with alterations in breast cancer. However, identification of the genes that are critical for tumorgenicity still remains a challenge. Here, we perform a comprehensive functional multi-omics analysis of somatic mutations in breast cancer and identify previously unknown key regulators of breast cancer tumorgenicity. We identify dysregulation of MYCBP2, an E3 ubiquitin ligase and an upstream regulator of mTOR signaling, is accompanied with decreased disease-free survival. We validate MYCBP2 as a key target through deplet

SUBMITTER: Neff RA 

PROVIDER: S-EPMC10331931 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature